IP Verse

Antiviral Agent - EP2266958

The patent EP2266958 was granted to Shionogi on Mar 15, 2017. The application was originally filed on Aug 8, 2002 under application number EP10178132A. The patent is currently recorded with a legal status of "Revoked".

EP2266958

SHIONOGI
Application Number
EP10178132A
Filing Date
Aug 8, 2002
Status
Revoked
Sep 13, 2019
Grant Date
Mar 15, 2017
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

MERCKNov 28, 2017MARSHALLADMISSIBLE

Patent Citations (12) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
OPPOSITIONGB2345058
OPPOSITIONUS2010068695
OPPOSITIONUS3244725
OPPOSITIONWO0026211
OPPOSITIONWO0039086
OPPOSITIONWO03030897
OPPOSITIONWO03035076
OPPOSITIONWO03035077
OPPOSITIONWO2004004657
OPPOSITIONWO2005074513
OPPOSITIONWO2012151567
SEARCHWO0039086

Non-Patent Literature (NPL) Citations (33) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- HSU, KUANG-KAN ET AL, "Synthesis of 2-(2-quinolyl)chromone derivatives", CA, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, Database accession no. 1978:169921, URL: STN-
EXAMINATION- HSU, KUANG-KAN ET AL, "Synthesis of 2-(2-quinolyl)chromone derivatives", TAIWAN KEXUE CODEN: TKHSAU; ISSN: 0371-845X, (1977), vol. 31, no. 3-4, pages 130 - 135-
EXAMINATION- ROONEY C S ET AL, "INHIBITORS OF GLYCOLIC ACID OXIDASE. 4-SUBSTITUTED 3-HYDROXY-1H-PYRROLE-2,5-DIONE DERIVATIVES", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, (19830101), vol. 26, no. 5, doi:10.1021/JM00359A015, ISSN 0022-2623, pages 700 - 714, XP000907286
OPPOSITION- Anonymous, "Data for Merck's Investigational Once-Daily Formulation of ISENTRESS (raltegravir) Show That at Week 48, a Regimen Containing the Once-Daily Dosing Formulation", (20160622), URL: http://investors.merck.com/news/press-release-details/2016/Data-for-Mercks-Investigational-Once-Daily-Formulation-of-ISENTRESS-raltegravir-Show-That-at-Week-48-a-Regimen-Containing-the-Once-Daily-Dosing-Formulation/default.aspx, XP055438003-
OPPOSITION- Anonymous, "Guideline on the clinical development of medicinal products for the treatment of HIV infection", European Medicines Agency, (20160428), pages 1 - 10, XP055438004-
OPPOSITION- Anonymous, "Isentress (raltegravir) Tablets )Highlights of prescribing information)", pages 1 - 24-
OPPOSITION- CHEMICAL ABSTRACTS, Database accession no. 1978:169921, XP055438008-
OPPOSITION- COUDERT et al., "Effect on free radical processes of some ascorbic acid analogues.", Biol. Pharm. Bull., (19960000), vol. 19, no. 2, pages 220 - 223, XP001026206-
OPPOSITION- Dicker et al., "19. SIMPLE AND ACCURATE IN VITRO METHOD FOR PREDICTING SERUM PROTEIN BINDING OF HIV INTEGRASE STRAND TRANSFER INHIBITORS", Dicker et al., NOURI NEAMARTI, HIV-1 Integrase: Mechanism and Inhibitor Design, John Wiley & Sons, pages 275 - 286, XP055437853-
OPPOSITION- Egbertson, et al., "HIV INTEGRASE INHIBITORS: FROM DIKETO ACIDS TO HETEROCYCLIC TEMPLATES: HISTORY OFHIV INTEGRASE MEDICINAL CHEMISTRY AT MERCK WEST POINT AND MERCK ROME (llIBM) LEADING TO DISCOVERY OF RALTEGRAVIR", Egbertson, et al., Nouri Neamati, et al., HIV-I Integrase: Mechanism and Inhibitor Design, First Edition., John Wiley & Sons, pages 197 - 229, XP055437852-
OPPOSITION- GEIN et al., "Synthesis and antimicrobial activity of 4-aroyl-3-hydroxy-2,5-dihydrofuran-2-ones and their derivatives", Pharmaceutical Chemistry Journal, (20000000), vol. 34, no. 5, pages 254 - 256, XP055438013-
OPPOSITION- Highlights of Prescribing Information for STRIBILD (elvitegravir-
OPPOSITION- Highlights of Prescribing Information for TIVICAY (dolutegravir-
OPPOSITION- Illustration of the effects of small structural changes-
OPPOSITION- Presentation material in relation to in vitro and in vivo activity of FUMDIP-
OPPOSITION- SATO et al., "Evaluation of an SIV-infected rhesus monkey model via integrase inhibition", URL: www.abstract-archive.org-
OPPOSITION- SMITH et al., "The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery", Nature Reviews/Drug Discovery, (20101200), vol. 9, pages 929 - 939, XP055438001-
OPPOSITION- UK technical primer-
OPPOSITION- GEIN et al., "Synthesis of 4-substituted 1-methyl-5-aryl- and 1,5-diaryltetrahydropyrrole-2,3-diones and their antiviral action", Pharmaceutical Chemistry Journal, vol. 25, no. 12, pages 884 - 887, XP008084957
OPPOSITION- SATO et al., "A simple and rapid method for preliminary evaluation of in vivo efficacy of anti-HIV compounds in mice", Antiviral Research, (19950000), vol. 27, pages 151 - 163, XP055437997
OPPOSITION- TAKASHI KAWASUJI et al., "3-Hydroxy-1,5-dihydro-pyrrol-2-one derivatives as advanced inhibitors of HIV integrase", Bioorganic & Medicinal Chemistry, (20070622), vol. 15, no. 16, pages 5487 - 5492, XP022130591
OPPOSITION- PETROCCHI et al., "From dihydroxypyrimidine carboxylic acids to carboxamide HIV-1 integrase inhibitors: SAR around the amide moiety", B & MCL Let ., (20070111), vol. 17, no. 2, pages 350 - 353, XP005827231
OPPOSITION- WAI et al., "Dihydroxypyridopyrazine-1,6-dione HIV-1 integrase inhibitors", Bioorganic & Medicinal Chemistry Letters, (20070914), vol. 17, no. 20, pages 5595 - 5599, XP022249674
OPPOSITION- ROONEY et al., "Inhibitors of glycolic acid oxidase. 4-substituted 3-hydroxy-1 H-pyrrole- 2,5-dione derivatives", Journal of Medicinal Chemistry, (19830000), vol. 26, no. 5, pages 700 - 714, XP002344691
OPPOSITION- SUMMA et al., "4,5-Dihydroxypyrimidine Carboxamides and N -Alkyl-5-hydroxypyrimidinone Carboxamides Are Potent, Selective HIV Integrase Inhibitors with Good Pharmacokinetic Profiles in Preclinical Species", J. Med. Chem., (20061101), vol. 49, no. 23, pages 6646 - 6649, XP055068250
OPPOSITION- PACE et al., "Dihydroxypyrimidine-4-carboxamides as Novel Potent and Selective HIV Integrase Inhibitors", J. Med. Chem., (20070000), vol. 50, no. 9, pages 2225 - 2239, XP055068254
OPPOSITION- KAWASUJI et al., "Carbamoyl Pyridone HIV-1 Integrase Inhibitors. 1. Molecular Design and Establishment of an Advanced Two-Metal Binding Pharmacophore", J. Med. Chem., (20121004), vol. 55, pages 8735 - 8744, XP055437845
OPPOSITION- CHENG et al., "Structure-based maximal affinity model predicts small-molecule druggability", Nature Biotechnology, (20070000), vol. 25, no. 1, pages 71 - 75, XP055437849
OPPOSITION- GROBLER et al., "Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes", PNAS, (20020514), vol. 99, no. 10, pages 6661 - 6666, XP002271568
OPPOSITION- AGRAWAL et al., "Probing chelation motifs in HIV integrase inhibitors", PNAS, (20120214), vol. 109, no. 7, pages 2251 - 2256, XP055231921
OPPOSITION- HAZUDA et al., "Inhibitors of strand transfer that prevent integration and inhibit HIV - 1 replication in cells", Science, (20000128), vol. 287, pages 646 - 650, XP002175834
OPPOSITION- YOSHINAGA et al., "Antiviral Characteristics of GSK1265744, and HIV Integrase Inhibitor Dosed Orally or by Long-Acting Injection", Antimicrobial Agents and Chemotherapy, (20150100), vol. 59, no. 1, pages 397 - 406, XP055437856
SEARCH- GEIN V.L. ET AL, "Synthesis of 4-substituted 1-methyl-5-aryl- and 1,5-diaryltetrahydropyrrole-2,3-diones and their antiviral action", PHARMACEUTICAL CHEMISTRY JOURNAL, SPRINGER, NEW YORK, NY, US, (1991), vol. 25, no. 12, ISSN 0091-150X, pages 884 - 887, XP008084957 [X] 1 * compounds I-IX *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents